

Tracy T Batchelor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1229763/publications.pdf>

Version: 2024-02-01

206
papers

13,814
citations

34105

52
h-index

23533

111
g-index

213
all docs

213
docs citations

213
times ranked

16747
citing authors

#	ARTICLE	IF	CITATIONS
1	Body CT and PET/CT detection of extracranial lymphoma in patients with newly diagnosed central nervous system lymphoma. <i>Neuro-Oncology</i> , 2022, 24, 482-491.	1.2	3
2	Improving Dâ€²â€²-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RFâ€²-receive/B₀-â€²shim array coils at 3â€²%T. <i>NMR in Biomedicine</i> , 2022, 35, 2.8 e4621.		2
3	Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. <i>Cancer</i> , 2022, 128, 47-58.	4.1	132
4	Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma. <i>Radiology</i> , 2022, 302, 410-418.	7.3	13
5	Factors associated with psychological distress in caregivers of patients with malignant gliomas. <i>Supportive Care in Cancer</i> , 2022, 30, 5811-5820.	2.2	3
6	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. <i>Neuro-Oncology</i> , 2022, 24, 1140-1149.	1.2	13
7	In Vivo Absolute Metabolite Quantification Using a Multiplexed ^{ERETICâ€²RX} Array Coil for Wholeâ€²Brain ^{MR} Spectroscopic Imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 121-133.	3.4	2
8	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. <i>Blood</i> , 2022, 139, 2306-2315.	1.4	62
9	Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2030-2030.	1.6	3
10	MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab060.	0.7	5
11	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). <i>Neuro-Oncology</i> , 2021, 23, 1056-1071.	1.2	68
12	Innovative Therapeutic Strategies for Primary CNS Lymphoma. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	1.8	1
13	Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 507-520.	1.8	41
14	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. <i>Nature Cancer</i> , 2021, 2, 498-502.	13.2	26
15	Intracranial Foreign Body Granuloma Mimicking Brain Tumor Recurrence: A Case Series. <i>Oncologist</i> , 2021, 26, e893-e897.	3.7	3
16	Integrating Advanced Practice Providers in an Academic Department of Neurology. <i>Neurology: Clinical Practice</i> , 2021, 11, 10.1212/CPJ.0000000000001077.	1.6	3
17	The 1994 National Cancer Instituteâ€²s strategy to fund multi-institutional, multidisciplinary consortia to design and conduct early phase clinical trials in patients with high grade gliomas.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2003-2003.	1.6	0
18	Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7506-7506.	1.6	18

#	ARTICLE	IF	CITATIONS
19	Treatment of Primary CNS Lymphoma: Maximizing Clinical Benefit, Minimizing Neurotoxicity. <i>Current Oncology Reports</i> , 2021, 23, 132.	4.0	5
20	Radiomics Repeatability Pitfalls in a Scan-Rescan MRI Study of Glioblastoma. <i>Radiology: Artificial Intelligence</i> , 2021, 3, e190199.	5.8	32
21	CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2021, 23, vi59-vi59.	1.2	4
22	CTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT) EXPERIENCE. <i>Neuro-Oncology</i> , 2021, 23, vi68-vi69.	1.2	0
23	BIOM-09. MYO-INOSITOL LEVELS ON MR SPECTROSCOPY CAN PREDICT FAILURE OF ANTI-ANGIOGENIC TREATMENT IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi11-vi12.	1.2	0
24	TAMI-29. MR SPECTROSCOPY MEASURES OF LAC/NAA AND NAA/CHO DIFFERENTIATE SURVIVORSHIP IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH ANTI-ANGIOGENIC THERAPY. <i>Neuro-Oncology</i> , 2021, 23, vi204-vi204.	1.2	0
25	INNV-40. REAL WORLD INTEGRATION OF THE NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN CLINICAL PRACTICE IN PATIENTS WITH IDH-WT GBM. <i>Neuro-Oncology</i> , 2021, 23, vi114-vi114.	1.2	0
26	Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 206-212.	7.0	48
27	Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1 α -mutated Human Gliomas. <i>Radiology</i> , 2020, 294, 589-597.	7.3	18
28	Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa157.	0.7	8
29	An integrated RF-receive/B0-shim array coil boosts performance of whole-brain MR spectroscopic imaging at 7 \AA T. <i>Scientific Reports</i> , 2020, 10, 15029.	3.3	12
30	Perceptions of prognosis and goal of treatment in patients with malignant gliomas and their caregivers. <i>Neuro-Oncology Practice</i> , 2020, 7, 490-497.	1.6	16
31	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020, 26, 1280-1284.	30.7	83
32	Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial. <i>Oncologist</i> , 2020, 25, 747-e1273.	3.7	9
33	Primary dural lymphomas: Clinical presentation, management, and outcome. <i>Cancer</i> , 2020, 126, 2811-2820.	4.1	24
34	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 371-377.	21.4	177
35	Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. <i>Neuro-Oncology</i> , 2020, 22, 94-102.	1.2	53
36	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543

#	ARTICLE	IF	CITATIONS
37	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	27.8	374
38	CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii43-ii44.	1.2	3
39	Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8042-8042.	1.6	4
40	Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3615-3615.	1.6	8
41	Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3617-3617.	1.6	2
42	MRI changes in patients with newly diagnosed glioblastoma treated as part of a phase II trial with baviximab, radiation, and temozolomide.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2546-2546.	1.6	0
43	HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, iii347-iii347.	1.2	2
44	CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2020, 22, ii44-ii44.	1.2	5
45	CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii50-ii51.	1.2	1
46	PATH-03. CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN IDH-WILDTYPE GLIOBLASTOMA: THE DANA-FARBER CANCER INSTITUTE EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, ii164-ii164.	1.2	0
47	CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii45-ii46.	1.2	0
48	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. <i>Cell</i> , 2019, 178, 835-849.e21.	28.9	1,408
49	BSCI-10. NEUROLOGICAL DYSFUNCTION CAUSED BY BRAIN TUMOR-GENERATED SOLID STRESS IS REVERSED BY LITHIUM. <i>Neuro-Oncology Advances</i> , 2019, 1, i2-i3.	0.7	0
50	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. <i>Journal of Neuro-Oncology</i> , 2019, 145, 97-105.	2.9	125
51	Accelerated progression of IDH mutant glioma after first recurrence. <i>Neuro-Oncology</i> , 2019, 21, 669-677.	1.2	38
52	Primary central nervous system lymphoma: A curable disease. <i>Hematological Oncology</i> , 2019, 37, 15-18.	1.7	53
53	Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. <i>Neuro-Oncology</i> , 2019, 21, 1412-1422.	1.2	128
54	Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. <i>Radiotherapy and Oncology</i> , 2019, 137, 95-101.	0.6	46

#	ARTICLE	IF	CITATIONS
55	Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. <i>Neuro-Oncology</i> , 2019, 21, 1118-1130.	1.2	37
56	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 741-750.	1.6	103
57	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4375-4387.	7.0	26
58	Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. <i>Blood</i> , 2019, 133, 2212-2221.	1.4	207
59	ACTR-61. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi27-vi27.	1.2	4
60	ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi20-vi21.	1.2	1
61	PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi186-vi186.	1.2	2
62	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. <i>Oncologist</i> , 2019, 24, 671-679.	3.7	36
63	MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. <i>Blood Advances</i> , 2019, 3, 375-383.	5.2	77
64	Is it time to revisit R-CHOP for primary CNS lymphoma?. <i>Blood</i> , 2019, 134, 221-222.	1.4	2
65	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. <i>Neuro-Oncology</i> , 2019, 21, vi111-vi111.	1.2	1
66	CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS. <i>Neuro-Oncology</i> , 2019, 21, vi58-vi59.	1.2	0
67	Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. <i>Clinical Cancer Research</i> , 2019, 25, 2305-2313.	7.0	43
68	Introduction of novel agents in the treatment of primary CNS lymphoma. <i>Neuro-Oncology</i> , 2019, 21, 306-313.	1.2	63
69	Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. <i>Nature Biomedical Engineering</i> , 2019, 3, 230-245.	22.5	127
70	Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. <i>Scientific Reports</i> , 2019, 9, 139.	3.3	9
71	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. <i>Neuro-Oncology</i> , 2019, 21, 596-605.	1.2	25
72	Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2019, 142, 69-77.	2.9	39

#	ARTICLE	IF	CITATIONS
73	Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. <i>Oncologist</i> , 2019, 24, 402-413.	3.7	3
74	Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3005-3005.	1.6	3
75	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. <i>Science</i> , 2018, 360, 331-335.	12.6	461
76	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. <i>Nature Communications</i> , 2018, 9, 1474.	12.8	106
77	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1240-1250.	1.2	64
78	Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss. <i>Neuro-Oncology</i> , 2018, 20, 289-291.	1.2	12
79	Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. <i>Neuro-Oncology</i> , 2018, 20, 642-654.	1.2	39
80	<i>Neuro-Oncology. Seminars in Neurology</i> , 2018, 38, 003-004.	1.4	0
81	Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. <i>Neuro-Oncology Practice</i> , 2018, 5, 64-68.	1.6	10
82	Glioblastoma in elderly patients: solid conclusions built on shifting sand?. <i>Neuro-Oncology</i> , 2018, 20, 174-183.	1.2	33
83	QOLP-23. PALLIATIVE CARE AND END OF LIFE HEALTHCARE UTILIZATION IN PATIENTS WITH INCURABLE PRIMARY MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018, 20, vi219-vi219.	1.2	0
84	Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. <i>Scientific Reports</i> , 2018, 8, 17062.	3.3	11
85	EPID-11. PROGRESSION OF IDH MUTANT GLIOMA AFTER FIRST RECURRENCE: DEVELOPMENT OF A FEASIBLE CLINICAL TRIAL ENDPOINT IN THE RECURRENT SETTING. <i>Neuro-Oncology</i> , 2018, 20, vi82-vi82.	1.2	0
86	CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. <i>Neuro-Oncology</i> , 2018, 20, vi56-vi57.	1.2	0
87	CSIG-34. PI3 KINASE PATHWAY ACTIVATION PROMOTES MALIGNANT PROGRESSION IN OLIGODENDROGLIAL TUMORS. <i>Neuro-Oncology</i> , 2018, 20, vi50-vi50.	1.2	0
88	ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi19-vi19.	1.2	3
89	QOLP-21. THE RELATIONSHIP BETWEEN CAREGIVING BURDEN AND ANXIETY SYMPTOMS IN CAREGIVERS OF PATIENTS WITH MALIGNANT GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi219-vi219.	1.2	0
90	NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE. <i>Neuro-Oncology</i> , 2018, 20, vi191-vi191.	1.2	0

#	ARTICLE	IF	CITATIONS
91	ACTR-33. TUMOR TISSUE PENETRATION AND PHARMACODYNAMICS OF ONC201 IN ADULT RECURRENT GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi18-vi19.	1.2	0
92	Primary central nervous system lymphoma. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641879356.	3.5	48
93	Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 4643-4649.	7.0	37
94	Primary Central Nervous System Lymphoma. <i>Neurologic Clinics</i> , 2018, 36, 517-532.	1.8	13
95	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8388-E8394.	7.1	40
96	Integrated clinical experience with ONC201 in H3 K27M glioma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2059-2059.	1.6	1
97	Intratumoral activity of ONC201 in adult recurrent glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14034-e14034.	1.6	2
98	MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14041-e14041.	1.6	1
99	Health care utilization and end of life care in patients with primary malignant brain tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14072-e14072.	1.6	0
100	Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor- β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now185.	1.2	28
101	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. <i>Neuro-Oncology</i> , 2017, 19, now235.	1.2	99
102	Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. <i>Neuro-Oncology</i> , 2017, 19, now253.	1.2	35
103	Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 132, 181-188.	2.9	16
104	New Directions in Anti-Angiogenic Therapy for Glioblastoma. <i>Neurotherapeutics</i> , 2017, 14, 321-332.	4.4	91
105	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i> -Mutant Cancers and Potentiates NAD ⁺ Depletion-Mediated Cytotoxicity. <i>Cancer Research</i> , 2017, 77, 4102-4115.	0.9	74
106	High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. <i>Cancer</i> , 2017, 123, 3073-3079.	4.1	41
107	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 361-369.	1.6	109
108	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. <i>Acta Neuropathologica</i> , 2017, 133, 1-3.	7.7	120

#	ARTICLE	IF	CITATIONS
109	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. <i>Npj Precision Oncology</i> , 2017, 1, 5.	5.4	49
110	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. <i>Npj Precision Oncology</i> , 2017, 1, .	5.4	16
111	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. <i>Clinical Cancer Research</i> , 2017, 23, 5745-5756.	7.0	53
112	cIMPACTâ€œNOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 27, 851-852.	4.1	63
113	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 603-610.	2.9	69
114	Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. <i>Npj Precision Oncology</i> , 2017, 1, 33.	5.4	27
115	High-dose Thiotepe, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 884-888.	0.4	14
116	EXTH-14. THE ALKYLATING CHEMOTHERAPEUTIC TEMOZOLOMIDE INDUCES METABOLIC STRESS AND POTENTIATES NAD+ DEPLETION-MEDIATED CELL DEATH IN IDH1 MUTANT CANCERS. <i>Neuro-Oncology</i> , 2017, 19, vi75-vi75.	1.2	0
117	NIMG-01. DIFFUSION MRI PHENOTYPES PREDICT OVERALL SURVIVAL BENEFIT FROM ANTI-VEGF MONOTHERAPY IN GLIOBLASTOMA AT FIRST OR SECOND RELAPSE. <i>Neuro-Oncology</i> , 2017, 19, vi142-vi143.	1.2	0
118	Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. <i>PLoS ONE</i> , 2017, 12, e0180541.	2.5	28
119	A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. <i>Oncotarget</i> , 2017, 8, 79298-79304.	1.8	119
120	Isocitrate dehydrogenase mutation as a therapeutic target in gliomas. <i>Chinese Clinical Oncology</i> , 2017, 6, 33-33.	1.2	30
121	Characterizing glioma microenvironment with ultra-high gradient diffusion MRI.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2050-2050.	1.6	0
122	NIMG-22. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA DURING CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE. <i>Neuro-Oncology</i> , 2016, 18, vi128-vi129.	1.2	0
123	NIMG-42. PENETRATION OF RADIOLABELED TEMOZOLOMIDE CORRELATES WITH CONTRAST ENHANCEMENT IN PATIENTS WITH RECURRENT GBM TREATED WITH BEVACIZUMAB. <i>Neuro-Oncology</i> , 2016, 18, vi133-vi133.	1.2	0
124	Glioblastoma care in the elderly. <i>Cancer</i> , 2016, 122, 189-197.	4.1	53
125	Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant<i>IDH</i> glioma patients. <i>Neuro-Oncology</i> , 2016, 18, now100.	1.2	30
126	Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 4452-4465.	7.0	112

#	ARTICLE	IF	CITATIONS
127	The role of whole brain radiation in primary CNS lymphoma. <i>Blood</i> , 2016, 128, 32-36.	1.4	35
128	Deformable image registration between pathological images and MR image via an optical macro image. <i>Pathology Research and Practice</i> , 2016, 212, 927-936.	2.3	18
129	Multimodality imaging and mathematical modelling of drug delivery to glioblastomas. <i>Interface Focus</i> , 2016, 6, 20160039.	3.0	34
130	Intra-axial brain tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 135, 253-274.	1.8	6
131	Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. <i>Journal of Clinical Neuroscience</i> , 2016, 31, 99-105.	1.5	8
132	Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. <i>Journal of Neuro-Oncology</i> , 2016, 126, 157-164.	2.9	64
133	Principles of pharmacotherapy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 149-162.	1.8	1
134	Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2016, 22, 2885-2896.	7.0	45
135	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. <i>Clinical Cancer Research</i> , 2016, 22, 1632-1641.	7.0	127
136	ATPS-852-HYDROXYGLUTARATE DEPLETION IS NOT SUFFICIENT TO INHIBIT GROWTH OF SEVERAL PROGRESSIVE IDH1 MUTANT SOLID CANCER TYPES. <i>Neuro-Oncology</i> , 2015, 17, v37.2-v37.	1.2	2
137	Computationally simple analysis of matched, outcome-based studies of ordinal disease states. <i>Statistics in Medicine</i> , 2015, 34, 2514-2527.	1.6	0
138	HCP-03NEWLY DIAGNOSED SINGLE BRAIN MASS – IMPLEMENTATION AND PERFORMANCE OF A HOSPITAL-WIDE MANAGEMENT PATHWAY. <i>Neuro-Oncology</i> , 2015, 17, v101.3-v101.	1.2	0
139	ANGI-04Olig2 REGULATES Wnt7b EXPRESSION AND VASCULATURE CHARACTERISTICS IN GLIOMA. <i>Neuro-Oncology</i> , 2015, 17, v41.4-v41.	1.2	0
140	NIMG-29RADIOLABELED TEMOZOLOMIDE CAN MEASURE BEVACIZUMAB INDUCED VASCULAR MODULATION IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2015, 17, v160.1-v160.	1.2	0
141	HCP-12IMPROVING THE EFFICIENCY OF MOLECULAR TESTING FOR EXPEDITED BRAIN TUMOR PATIENT MANAGEMENT AND CLINICAL TRIAL ENROLLMENT. <i>Neuro-Oncology</i> , 2015, 17, v103.4-v104.	1.2	0
142	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. <i>Cancer Cell</i> , 2015, 28, 773-784.	16.8	327
143	Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. <i>Neuro-Oncology</i> , 2015, 17, 862-867.	1.2	111
144	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. <i>Neurology</i> , 2015, 84, 280-286.	1.1	92

#	ARTICLE	IF	CITATIONS
145	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3610-3618.	7.0	79
146	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	9.4	821
147	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1386-1392.	1.2	50
148	Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients. <i>Translational Oncology</i> , 2015, 8, 137-146.	3.7	38
149	Standard chemoradiation for glioblastoma results in progressive brain volume loss. <i>Neurology</i> , 2015, 85, 683-691.	1.1	70
150	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. <i>Neuro-Oncology</i> , 2015, 17, 116-121.	1.2	207
151	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2025-2025.	1.6	1
152	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS2080-TPS2080.	1.6	1
153	Genomic profiling of brain metastases: current knowledge and new frontiers. <i>Chinese Clinical Oncology</i> , 2015, 4, 22.	1.2	16
154	AT-37PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2014, 16, v16-v17.	1.2	0
155	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>i>IDH</i>-Mutant Gliomas. <i>Clinical Cancer Research</i>, 2014, 20, 2898-2909.</i>	7.0	146
156	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. <i>Cancer Discovery</i> , 2014, 4, 1299-1309.	9.4	207
157	AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA. <i>Neuro-Oncology</i> , 2014, 16, v16-v16.	1.2	0
158	ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples. <i>Blood</i> , 2014, 124, 5219-5219.	1.4	2
159	Phase II trial of the phosphatidylinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2019-2019.	1.6	9
160	Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2020-2020.	1.6	1
161	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2031-2031.	1.6	2
162	Longitudinal diffusion MRI in PCNSL treated with methotrexate, rituximab, and temozolomide (MRT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8579-8579.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Targetable signaling pathway mutations and progression of IDH<i>/i>-mutant glioma.. Journal of Clinical Oncology, 2014, 32, 2061-2061.	1.6	0
164	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results.. Journal of Clinical Oncology, 2014, 32, 2027-2027.	1.6	0
165	ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells.. Journal of Clinical Oncology, 2014, 32, e13022-e13022.	1.6	0
166	Probabilistic atlas-based segmentation of combined T1-weighted and DUTE MRI for calculation of head attenuation maps in integrated PET/MRI scanners. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 160-71.	1.0	23
167	Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology, 2013, 31, 3212-3218.	1.6	489
168	Multicenter phase I trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood, 2013, 121, 745-751.	1.4	105
169	Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2013-2013.	1.6	16
170	Phase II trial of the phosphatidylinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, 2015-2015.	1.6	2
171	Association of PIK3CA-activating mutations with more disseminated disease at presentation and earlier recurrence in glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2029-2029.	1.6	7
172	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2054-2054.	1.6	3
173	Antiangiogenic Therapy for Glioblastoma: The Challenge of Translating Response Rate into Efficacy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e71-e78.	3.8	5
174	Update on Glioma Treatments in the United States. Japanese Journal of Neurosurgery, 2013, 22, 590-596.	0.0	0
175	Case 17-2012. New England Journal of Medicine, 2012, 366, 2112-2120.	27.0	3
176	Response to C. Massard et al. Journal of Clinical Oncology, 2012, 30, 563-564.	1.6	0
177	Detection of 2-Hydroxyglutarate in IDH<i>/i>-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy. Science Translational Medicine, 2012, 4, 116ra4.	12.4	367
178	Prospective, high-throughput molecular profiling of human gliomas. Journal of Neuro-Oncology, 2012, 110, 89-98.	2.9	47
179	Effects of cediranib, a VEGF signaling inhibitor, in combination with chemoradiation on tumor blood flow and survival in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2012, 30, 2009-2009.	1.6	7
180	Effect of antiangiogenic therapy on tumor-associated macrophages in recurrent glioblastoma.. Journal of Clinical Oncology, 2012, 30, 2010-2010.	1.6	1

#	ARTICLE	IF	CITATIONS
181	Effects of cediranib (VEGF signaling inhibitor) on edema in newly diagnosed glioblastoma patients during initial chemoradiation.. Journal of Clinical Oncology, 2012, 30, 2012-2012.	1.6	14
182	Impact of adjuvant anti-VEGF therapy on treatment-related pseudoprogression in patients with newly diagnosed glioblastoma receiving chemoradiation with or without anti-VEGF therapy.. Journal of Clinical Oncology, 2012, 30, 2025-2025.	1.6	3
183	Response of nonenhancing regions in glioblastoma to VEGF-signaling inhibitor cediranib correlates with tumor infiltration.. Journal of Clinical Oncology, 2012, 30, 3036-3036.	1.6	0
184	Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2012, 30, 2005-2005.	1.6	1
185	Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium. Oncologist, 2011, 16, 1589-1599.	3.7	386
186	Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma. Blood, 2011, 118, 959-959.	1.4	0
187	Phase II Study of Cediranib, an Oral Panâ€“Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology, 2010, 28, 2817-2823.	1.6	489
188	High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro-Oncology, 2009, 11, 211-215.	1.2	115
189	High-Dose Methotrexate, Rituximab, and Temozolomide (MRT) for Patients with Primary CNS Lymphoma (PCNSL).. Blood, 2009, 114, 1672-1672.	1.4	3
190	Supportive Care of Brain Tumor Patients. Hematology/Oncology Clinics of North America, 2006, 20, 1337-1361.	2.2	55
191	Primary CNS Lymphoma. Journal of Clinical Oncology, 2006, 24, 1281-1288.	1.6	329
192	Isolated Brain Parenchyma Relapse of Non-Hodgkinâ€™s Lymphoma (NHL): A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG).. Blood, 2006, 108, 2026-2026.	1.4	2
193	Neuro-oncology update: 2005. Current Opinion in Neurology, 2005, 18, 631.	3.6	3
194	Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma. Journal of Clinical Oncology, 2005, 23, 5034-5043.	1.6	729
195	Results of Whole-Brain Radiation As Salvage of Methotrexate Failure for Immunocompetent Patients With Primary CNS Lymphoma. Journal of Clinical Oncology, 2005, 23, 1507-1513.	1.6	220
196	International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) Study on Low-Grade Primary Central Nervous System Lymphoma in Immunocompetent Patients.. Blood, 2005, 106, 3343-3343.	1.4	7
197	Treatment of Relapsed Central Nervous System Lymphoma with High-Dose Methotrexate. Clinical Cancer Research, 2004, 10, 5643-5646.	7.0	196
198	Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. Neuro-Oncology, 2004, 6, 21-27.	1.2	98

#	ARTICLE	IF	CITATIONS
199	Primary Central Nervous System Lymphoma of T Cell Origin: A Descriptive Analysis of 45 Cases from the International PCNSL Collaborative Group.. Blood, 2004, 104, 1372-1372.	1.4	0
200	Treatment of Primary CNS Lymphoma With Methotrexate and Deferred Radiotherapy: A Report of NABTT 96â€“07. Journal of Clinical Oncology, 2003, 21, 1044-1049.	1.6	499
201	High-dose methotrexate for intraocular lymphoma. Clinical Cancer Research, 2003, 9, 711-5.	7.0	121
202	Cytotoxic chemotherapy: Advances in delivery, pharmacology, and testing. Current Oncology Reports, 2000, 2, 445-453.	4.0	14
203	New Treatment Strategies for Malignant Gliomas. Oncologist, 1999, 4, 209-224.	3.7	147
204	Intraocular Methotrexate Level After High-Dose Intravenous Infusion. Journal of Clinical Oncology, 1999, 17, 1326c-1326c.	1.6	36
205	Central nervous system lymphoma. , 0, , 449-461.		0
206	Deep Learning Super-resolution MR Spectroscopic Imaging of Brain Metabolism and Mutant IDH Glioma. Neuro-Oncology Advances, 0, , .	0.7	2